Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.30 +0.4%	$1.23	$1.05 ▼ $10.16	$40.45M	1.64	268,025 shs	125,785 shs
IPSC Century Therapeutics	$0.56 +0.9%	$0.56	$0.34 ▼ $3.29	$47.83M	1.78	552,946 shs	214,228 shs
OSTX OS Therapies	$1.87 -2.1%	$1.79	$1.12 ▼ $7.00	$52.54M	N/A	491,386 shs	8.01 million shs
PHGE BiomX	$0.45 -39.4%	$0.50	$0.34 ▼ $3.86	$11.52M	1.41	106,529 shs	53,300 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	+7.92%	+5.28%	-14.24%	-78.91%
IPSC Century Therapeutics	0.00%	+7.96%	-1.23%	+27.53%	-75.33%
OSTX OS Therapies	0.00%	+1.63%	+12.65%	+33.57%	+186,999,900.00%
PHGE BiomX	0.00%	-2.40%	-8.76%	-21.27%	-87.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.6421 of 5 stars	3.5	2.0	0.0	0.0	1.1	3.3	0.6
IPSC Century Therapeutics	2.77 of 5 stars	3.5	3.0	0.0	0.0	2.2	1.7	0.6
OSTX OS Therapies	2.6581 of 5 stars	3.7	0.0	0.0	0.0	2.4	1.7	0.6
PHGE BiomX	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,267.90% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	650.00% Upside
OSTX OS Therapies	3.40	Buy	$18.00	862.57% Upside
PHGE BiomX	3.00	Buy	$21.00	4,587.50% Upside

Current Analyst Ratings Breakdown

Latest PHGE, OSTX, ACRV, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
IPSC Century Therapeutics	$6.59M	7.32	N/A	N/A	$1.90 per share	0.29
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest PHGE, OSTX, ACRV, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
IPSC Century Therapeutics	N/A	11.70	11.70
OSTX OS Therapies	N/A	0.76	0.76
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
IPSC Century Therapeutics	50.20%
OSTX OS Therapies	N/A
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
IPSC Century Therapeutics	5.00%
OSTX OS Therapies	13.80%
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable

PHGE, OSTX, ACRV, and IPSC Headlines

Recent News About These Companies

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

April 1, 2025 | globenewswire.com

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

March 31, 2025 | globenewswire.com

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

March 25, 2025 | globenewswire.com

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

March 19, 2025 | globenewswire.com

BiomX reports “impressive” data in first bacteriophage trial

February 21, 2025 | pharmaphorum.comP

BiomX regains compliance with NYSE American continued listing standards

December 17, 2024 | markets.businessinsider.com

BiomX shares hold Buy rating from H.C. Wainwright on Q3 results

November 17, 2024 | uk.investing.com

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

November 14, 2024 | globenewswire.com

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

November 12, 2024 | globenewswire.com

BiomX Announces a Mandatory Unit Separation

October 15, 2024 | globenewswire.com

BiomX Stock Gains From Favorable Study Data Presentation on BX004

September 20, 2024 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, OSTX, ACRV, and IPSC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.30 +0.01 (+0.39%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$1.30 0.00 (0.00%)

As of 07/3/2025 04:27 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Century Therapeutics NASDAQ:IPSC

$0.56 +0.01 (+0.90%)

Closing price 07/3/2025 02:21 PM Eastern

Extended Trading

$0.56 0.00 (0.00%)

As of 07/3/2025 04:13 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

OS Therapies NYSE:OSTX

$1.87 -0.04 (-2.09%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$1.88 +0.01 (+0.80%)

As of 07/3/2025 04:54 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

BiomX NYSEMKT:PHGE

$0.45 -0.29 (-39.38%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$0.44 -0.01 (-1.79%)

As of 07/3/2025 05:00 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time